Optimizing MALDI-TOF Use. Clinical Impact Laboratory Impact

Similar documents
VITEK MS Implementation of Mass Spectrometry

ESCMID Online Lecture Library. by author

Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification

SUPPLEMENTARY MATERIAL

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Tandem MS in Microbiology. Chris Doern, PhD D(ABMM) UT Southwestern Medical Center Dallas, TX

National Surveillance of Nosocomial Septicemia (Hospital-wide)

Supplemental Digital Content

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

MALDI-TOF mass spectrometry for direct bacterial identification

Disclosures! Infection & Nonunions. Infection workup. Skip early infection. Culture (+) fractures. Gross Infection

Original Article Clinical Microbiology INTRODUCTION

BACTERIOLOGY PROFICIENCY TESTING PROGRAM

OVERVIEW OF CURRENT IDENTIFICATION SYSTEMS AND DATABASES

Sep Oct Nov Dec Total

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year )

Normal Human Flora. (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine

Cell counting (EtBr) Before cell-lysis. Cell-lysis by 3% SDS beads beating. After cell-lysis

Brief Communication Clinical Microbiology

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

Work up of Respiratory & Wound Cultures:

Microsan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #

M E D I C A L L A B O R A T O R Y

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05

Bacterial Screening of Platelet Concentrates

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

BACTERIOLOGY PROFICIENCY TESTING PROGRAM

BACTERIOLOGY PROFICIENCY TESTING PROGRAM

KOMAR UNIVERSITY OF SCIENCE AND TECHNOLOGY (KUST) Medical Bacteriology Syllabus (Theory) Spring 2016

CONSIDERATIONS IN UTI DETECTION AND POTENTIAL IMPACT ON ANTIBIOTIC STEWARDSHIP

Consultation on the Revision of Carbapenem Breakpoints

Treatment of febrile neutropenia in patients with neoplasia

Work-up of Respiratory Specimens Now you can breathe easier

12/12/2011. Atypical Pneumonia. Objectives. Causative Agents of Acute Pneumonia Bacteria. Causative Agents of Acute Pneumonia Other Agents

MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1)

Supplementary Figure 1

TITLE: MALDI-TOF Mass Spectrometry for Bacterial Species Identification: A Review of Diagnostic Accuracy and Clinical and Cost-Effectiveness

Clinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

BACTERIOLOGY PROFICIENCY TESTING PROGRAM

Received 1 March 2011/Returned for modification 19 April 2011/Accepted 20 May 2011

Direct identification of bacteria from positive anaerobic BacT/Alert blood cultures by. Contents Category: Diagnostics, typing and identification

MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Patient Information Leaflet

Efficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #

1430 West McCoy Lane Santa Maria, CA p:

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Chain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host

In the absence of underlying edema or other skin abnormalities, erysipelas

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Life-threatening infections. Frank Bowden October 5, 2018

NEONATAL SEPSIS. Dalima Ari Wahono Astrawinata Departemen Patologi Klinik, FKUI-RSCM

Mongolia September 2012

Identification of bacteria directly from positive blood culture samples by DNA pyrosequencing of the 16S rrna gene

Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Blood cultures are frequently used to evaluate

Labquality External Quality Assessment Programmes General Bacteriology 1 2/2013

Int.J.Curr.Microbiol.App.Sci (2016) 5(9):

Medical Microbiology, University Hospital of Liège, Liège, Belgium

IMMUVIEW S. PNEUMONIAE ANTIGEN TEST. Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid.

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx Only

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx only

The role of an AMR reference laboratory

MALDI-TOF Mass Spectrometry: A New Rapid ID Method in Clinical Microbiology

General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since

Scottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service

Infection Data: Form Updates

Class 15. Infections of the Central Nervous System

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015

DNA pyrosequencing of the 16S rrna

Staphylococci. Gram stain: gram positive cocci arranged in clusters.

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014

Bacterial composition in the supragingival plaques of children with and without dental caries

CONTAMINATION, SPOILAGE, CONTAMINATION AND PRESERVATION OF FOOD (CONTINUED)

INTRA-ABDOMINAL INFECTIONS - II

Anaerobes Bacteroides species, Clostridium species (Note: most strains of C.difficile are resistant).

Aerobic bacteria isolated from diabetic septic wounds

Cefuroxime (as sodium)

Ceftizoxime in the treatment of infections in patients with cancer

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

The Public Health Benefit of CRE Colonization Testing

Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples

Intestinal colonization in premature and very low birth weight infants: Influencing factors and necrotizing enterocolitis (NEC)

COONa CH 2 OCOCH 3 CONH H

Clinical experience with ceftazidime in urology in Japan

EDUCATIONAL COMMENTARY THROAT CULTURES LEARNING OUTCOMES. Upon completion of this exercise, the participant should be able to:

The Clinical Significance of Blood Cultures. Presented BY; Cindy Winfrey, MSN, RN, CIC, DON- LTC TM, VA- BC TM

RESEARCH ARTICLE Torres et al., Journal of Medical Microbiology 2017;66: DOI /jmm

Update on CLSI and EUCAST

MERREM IV. meropenem PRODUCT INFORMATION COOH CH 3

ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul

MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions

Transcription:

Optimizing MALDI-TOF Use Clinical Impact Laboratory Impact Christine C. Ginocchio, PhD, MT (ASCP) Clinical Professor of Medicine Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs, biomerieux VP, Global Medical and Scientific Affairs, BioFire Dx

Power Ionising Vacuum Negative MALDI-TOF Mass Spectrometry 2

CLINICAL APPLICATIONS BEYOND BACTERIAL ISOLATE IDENTIFICATION DIRECT DETECTION AND DIRECT AST FROM POSITIVE BLOOD CULTURES

Gram stain impacted 42 cases (20.8%) MALDI-TOF ID led to a modification of empirical therapy in 71 of all 202 cases (35.1%), and in 16 of 27 cases (59.3%) of monomicrobial bacteremia caused by AmpC-producing Enterobacteriaceae. The most frequently observed impact was an early appropriate broadening of the antibiotic spectrum in 31 of 71 cases (43.7%). In total, 143 of 165 episodes (86.7%) of monomicrobial bacteremia were correctly identified at genus level by MALDI-TOF. 4

In 202/259 bottles where VITEK MS (Saramis database) was able to generate an ID, 189 (93.6%) were correct to the species level, whereas the IDs provided for 7 isolates (3.5%) were incorrect. 5

VITEK MS:1242 Bottles/901 Isolates Achromobacter sp. Acinetobacter spp. (2) Aeromonas sp. Citrobacter spp. (2) E. coli Enterobacter spp. (2) H. influenzae Klebsiella spp. (2) Morganella morganii Pasturella multocida Proteus spp. (3) Providencia spp. (2) Pseudomonas spp. (3) Serratia spp. (2) Steno. maltophilia (species number) Abiotrophia sp. Actinomyces spp. (2) AHS (10) Bacteroides spp. (7) Beta strep groups B, C, G Clostridium spp. (2) CNS (7) Fusobacterium spp. (2) Enterococcus spp. (3) Peptostreptococcus (1) Micrococcus luteus Prevotella buccae Staph aureus Stomatococcus sp. Strep. bovis Strep. pneumoniae Candida spp. (6) Bacillus spp. (2) C. neoformans Corynebacterium spp. (3) Rhodotorula spp. (2) Eubacterium sp. Trichosporon asahii Lactobacillus acidophilus Listeria monocytogenes Nocardia spp. (2) Rothia denticarosa Off label use: Laboratory validated 6

Blood ID using VITEK MS RUO, MS IVD and Combination of MS IVD and MS RUO Total ID ID Family ID Genus ID Genus ID Genus No ID N=632 N (%) only only and species and/or species N (%) N (%) N (%) N (%) N (%) MS RUO 80.1% 1.9% 3.0% 75.2% 78.2% 19.9% MS IVD 84.7% 0.0% 0.2% 84.5% 84.7% 15.3% MS IVD/ MS RUO 86.4% 0.0% 0.6% 85.8% 86.4% 13.6% Discordant between MS RUO and MS IVD were to species level 2 Staph delphini/intermedius (RUO) called Staph pseudointermedius (IVD) 2 Staph warneri (RUO) called Staph pasteuri (IVD) In both cases the two choices reside in the same taxonomic groups. One Strep mitis/oralis (RUO) was called Strep pneumoniae (IVD) confirmed to be Strep pneumoniae by 16s rrna gene sequencing Off label use: Laboratory validated 7

Comparison of VITEK MS Blood ID to ID of Isolates by Conventional Methods ID Family ID Genus ID Genus and ID Genus No N=546 only only species and/or species Correlation a N (%) N (%) N (%) N (%) N (%) MS IVD/RUO 0.0% 0.9% 99.1% 100.0% - Conventional 0.0% 22.3% b 77.7% b 100.0% - Correlation 0.4% 23.3% b 76.2% b 99.4% 0.2% a a 1 Corynebacterium sp. was called Actinomyces neuii (IVD/RUO) and confirmed to be Actinomyces neuii by 16s rrna gene sequencing b For conventional testing, coagulase negative Staphylococcus spp., Bacillus spp., Corynebacterium spp. and alpha hemolytic streptococci from single blood cultures are not routinely identified to species level Off label use: Laboratory validated 8

9

10

11

Off label use: Laboratory validated 12

Performance of Direct Testing 13

14

15

Beta lactamase with cefotaxime Discrimination between E. coli strains that were R or S to aminopenicillins and R to 3rd-generation cephalosporins in Enterobacteriaceae that constitutively produced class C lactamases had a with a sensitivity and a specificity of 100%. Discrimination was more difficult in species expressing class A -lactamases, as these enzymes can generate false-positive results. Thus, the sensitivity and specificity for this group were 100% and 91.5%, respectively. Cefotaxime 16

Game Changers: Time to Accurate ID Time to ID: hours versus weeks Accuracy and subspecies determinations 17

Tested 140 strains representing 17 genera and 22 species Results compared to sequencing/molecular probes 18

Differentiate closely related species and species within a genus 19

Mather et al. JCM 2014:52;130. 20

WORKFLOW IMPROVEMENTS

22 22

Omai Garner, PhD, D(ABMM) Assistant Clinical Professor Department of Pathology and Laboratory Medicine Associate Director of Clinical Microbiology Traditional anaerobe identification and AST Total time for Identification 5 days Total time for Identification and Sensitivities amount of time on possible inappropriate therapy 7 days MALDI-TOF Total time for Identification and sensitivities (anaerobic coverage for treatment) 2 days Large clinical impact 3 day improvement in turn around time for patient Lab impact Saves CLS time on the bench, no aero tolerance test (multiple plates), no rapid ANA or other biochemical tests May allow a lab to offer 7 day a week coverage ASM Annual Meeting, Boston 2014 23

Hands on Time/Time to Results Microscan/Conventional Set Up: 48 samples Order: 30 sec/panel Set up: 1 min/panel Total hands on time: 72 min Microscan/Conventional Time to ID/48 samples Read time: 18-24-36-48 hr Microscan/Conventional Time to ST 18 to 48 hr MALDI-TOF: Set Up: 48 samples/3 calibrators Write the directory of samples:5 min Prepare full slide/calibrators: 25 min Create template in the computer with ID and lot numbers: 5 min Place slide into instrument: 1 min Total hands on time: 36 min MALDI-TOF Time to ID Load and re-pressurize: 7 min Read calibrators and 1 acquisition zone: 15 min Time to first results: 22 min / next 16 results: 15 min Complete 48 wells and calibrator x6: 52 +/- 2 min Vitek II Time to AST 6 to 24 hr 24

Change in Laboratory Workflow Shift 1: 11 PM to 7AM Blood Cultures Gram stains Processing Day 1: Shift 2: 6 AM to 5 PM 4 hour work increments Day 2: Shift 2 Release 6 AM to 10 AM, 10 AM to 2 PM ID and AST results available 20-24 hr: 75% after rounds: 18-24 hr Day 1: Shift 3: 4 PM to 1 AM 4 hour work increments Day 2: Shift 3: Release 4 PM to 8 PM, 8 PM to 12 AM ID and AST results available 20-24 hr: results after rounds: 8-16 hr 25

Change in Laboratory Workflow Shift 1: 11 PM to 7AM Blood Cultures Gram stains Processing Day 1: Shift 2: 6 AM to 5 PM 4 hour work increments Day 1: Shift 3: Release 4 PM to 8 PM, 8 PM to 12 AM ID: 1.5 hr: AST results available 8-12 hr: 95% before rounds rounds Day 1: Shift 3: 4 PM to 1 AM 4 hour work increments Day 2: Shift 1, 2: Release 4 AM to 10 AM, 10 AM to 2 PM ID: 1.5 hr: AST results available 8-12 hr: 12 hours earlier 26

27